
Syncom Formulations (India) Ltd. (SYNCOMF): Syncom Formulations Share Price Rises 9.21% Today
Updated: 7 Oct 2026 • 10:25 am
Posted by:

Syncom Formulations Share Price is rising today after the stock moved to Rs 25.38, up 9.21%, with market capitalisation at Rs 2,173.28 crore. The latest Univest figures show a clear price rise versus the previous close, but no company-specific catalyst is established. For readers tracking Syncom Formulations Share Price Today, the main relevance is the size of the move, the intraday range and the valuation backdrop in Healthcare. According to Univest data, the stock opened at Rs 23.14, touched Rs 25.38 and traded between Rs 23.10 and Rs 25.38 as of 07 October 2026 at 10:22:41 AM IST. In this Syncom Formulations Share Price update, investors can monitor whether the move stays aligned with the company’s P/E, P/B and return ratios while the broader healthcare pack remains part of the Market Update.
Syncom Formulations Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 25.38 |
| Previous Close | Rs 23.24 |
| Today's Move | Rs 2.14 (+9.21%) |
| Open | Rs 23.14 |
| High | Rs 25.38 |
| Low | Rs 23.1 |
| Market Capitalisation | Rs 2,173.28 crore |
| Market Cap Category | Small Cap |
Syncom Formulations (India) Ltd. (SYNCOMF) rose to Rs 25.38 from the previous close of Rs 23.24, a move of Rs 2.14 or 9.21%. The stock opened at Rs 23.14, reached a high of Rs 25.38, recorded a low of Rs 23.1.
Syncom Formulations Share Price Today shows a strong intraday rise from the previous close, with the stock trading at Rs 25.38 against Rs 23.24, a gain of Rs 2.14 or 9.21%. The share opened at Rs 23.14, moved within a band of Rs 23.10 to Rs 25.38 and last traded at the day’s high. Syncom Formulations Share Price therefore reflects a sharp price action move rather than a change that can be attributed to a verified company event. According to latest Univest data, the market capitalisation stands at Rs 2,173.28 crore, which keeps the stock within the Healthcare universe while the price rise remains the core headline. For readers following Syncom Formulations Share Price Live, the immediate focus is the extent of the move versus the previous close and whether the stock can sustain this level. That takes the discussion naturally to Syncom Formulations Share Price and fundamental context.
Syncom Formulations (India) Ltd. (SYNCOMF) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,173.28 crore |
| P/E Ratio | 25.54x |
| P/B Ratio | 4.97x |
| ROE | 20.19% |
| ROCE | 26.8% |
| EPS | Rs 0.91 |
| Book Value Per Share | Rs 4.68 |
| Dividend Yield | 0.43% |
Syncom Formulations (India) Ltd. (SYNCOMF) fundamental metrics show P/E 25.54x, P/B 4.97x, ROE 20.19%, ROCE 26.8%. Read together, these ratios describe the company's position rather than a recommendation.
Syncom Formulations (India) Ltd. has a market capitalisation of Rs 2,173.28 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 25.54x, P/B at 4.97x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 20.19% and ROCE of 26.8%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 0.91, book value per share of Rs 4.68, dividend yield of 0.43%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.15x, median ROE of 11.73%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 25.54x |
| Benchmark Median P/E | 32.15x |
| Benchmark Average P/E | 48.45x |
| Benchmark P/E Range | 3.58x to 695.67x |
| Company P/B Ratio | 4.97x |
| Benchmark Median P/B | 2.96x |
| Company ROE | 20.19% |
| Benchmark Median ROE | 11.73% |
| Company ROCE | 26.8% |
| Benchmark Median ROCE | 13.63% |
| Company Market Capitalisation | Rs 2,173.28 crore |
| Benchmark Median Market Cap | Rs 816.35 crore |
Syncom Formulations (India) Ltd. (SYNCOMF) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 25.54x, which is below the benchmark median of 32.15x, a difference of -20.56%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Syncom Formulations (India) Ltd. (SYNCOMF) has a ROE of 20.19%, which is above the benchmark median of 11.73%, a difference of +72.12%. Syncom Formulations (India) Ltd. (SYNCOMF) has a ROCE of 26.8%, which is above the benchmark median of 13.63%, a difference of +96.63%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,27,561.49 | 35.73 | 5 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,44,572.22 | 86.63 | 14.35 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,80,870.62 | 83.33 | 20.25 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,13,565.81 | 25.64 | 4.29 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,07,769.94 | 32.19 | 3.09 | 11.83 | 16 |
Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 25.54x compared with the displayed peer median of 35.73x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 20.19% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 26.8% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Syncom Formulations (India) Ltd. (SYNCOMF) has a market capitalisation of Rs 2,173.28 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Syncom Formulations
- Syncom Formulations Share Price is up 9.21%, making it one of the clearer Stocks Rising Today in the Healthcare pack.
- Syncom Formulations Share Price is trading at Rs 25.38 versus a previous close of Rs 23.24, so the price action is easy to follow on the chart and in Syncom Formulations Stock News.
- Syncom Formulations Share Price is supported by ROE of 20.19% and ROCE of 26.80%, both above the same-industry benchmark.
- Syncom Formulations Share Price has a P/E of 25.54, which is below the sector median and average for Pharmaceuticals & Drugs.
- Syncom Formulations Share Price is being tracked alongside Healthcare sector performance and peer valuation in the Indian Stock Market.
About Syncom Formulations
Syncom Formulations (India) Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. Syncom Formulations Share Price therefore belongs to a business that is evaluated through pricing power, capital efficiency and product economics rather than broad market themes alone. The company description available in the latest Univest figures identifies it by sector and industry, which places Syncom Formulations Share Price within a regulated and competitive pharmaceutical environment. For readers following Syncom Formulations Company News, the important point is that the stock’s daily move should be read alongside return ratios, valuation multiples and the industry benchmark. Syncom Formulations Share Price also matters because the company’s current market capitalisation positions it well above the median company size in its same-industry benchmark. That gives Syncom Formulations Share Price a clearer comparison base against listed healthcare peers when reviewing Syncom Formulations Earnings, market cap and relative valuation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is Syncom Formulations Share Price today?
Ans. Syncom Formulations Share Price is Rs 25.38, up 9.21% from the previous close of Rs 23.24. The stock also traded between Rs 23.10 and Rs 25.38 during the reported period, with market capitalisation at Rs 2,173.28 crore.
Why is Syncom Formulations Share Price rising today?
Ans. Univest data confirms the move itself, though no company-specific trigger has been identified. Syncom Formulations Share Price is higher by Rs 2.14, and the move is visible in the day’s open, high, low and last traded price.
What does the Syncom Formulations Share Price move show?
Ans. Syncom Formulations Share Price shows a clear intraday gain from Rs 23.24 to Rs 25.38. The stock opened at Rs 23.14 and reached the day’s high, which makes the price action important for short-term tracking.
Is Syncom Formulations Share Price expensive compared with peers?
Ans. Syncom Formulations Share Price has a P/E of 25.54 and a P/B of 4.97. That P/E is below the sector median of 32.15 and average of 48.45, while the P/B is above the sector median of 2.96.
How does Syncom Formulations perform on returns?
Ans. Syncom Formulations Share Price is backed by ROE of 20.19% and ROCE of 26.80%. Both figures stand above the same-industry benchmark medians, which gives the stock a stronger return profile than many peers.
What are the key valuation numbers for Syncom Formulations Share Price?
Ans. Syncom Formulations Share Price is linked to EPS of Rs 0.91, book value of Rs 4.68 and dividend yield of 0.43%. These figures help explain the stock’s valuation alongside its P/E and P/B ratios.
How does Syncom Formulations compare with Healthcare peers?
Ans. Syncom Formulations Share Price is much smaller in market-cap terms than Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, but its P/E is close to Zydus Lifesciences and below several other peers.
What sector does Syncom Formulations belong to?
Ans. Syncom Formulations Share Price belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That sector context matters because the stock is being compared with 199 companies in the same industry benchmark.
Track Syncom Formulations Share Price on Univest
Use Syncom Formulations (India) Ltd. (SYNCOMF) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Track Syncom Formulations Share Price on Univest to follow live price movement, market capitalisation, P/E, P/B, ROE, ROCE, EPS, book value and dividend yield in one place. Syncom Formulations Share Price Today can also be reviewed with 52-week levels and broader market insights when needed. For readers comparing Syncom Formulations Share Price with Healthcare peers, Univest keeps the company’s valuation and stock performance in a single view. The platform also helps readers revisit Syncom Formulations Stock News, Syncom Formulations Latest News and Syncom Formulations Share Price Update without losing the valuation context that matters most in fundamental analysis.
Recent Articles

US Fed Rate Hike: American Inflation Heats Up, Impact on Indian Equity, Rupee and Gold
16 October 2026

31% Rally in 2 Weeks: Orient Electric Stock Jumps Post Q2
16 October 2026

Tech Mahindra Dividend, Bonus Share 2026: Should You Buy Ahead of Record Date?
16 October 2026

Ambani Taps Massive Reliance Workforce to Boost Jio's Record IPO
16 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
US Fed Rate Hike: American Inflation Heats Up, Impact on Indian Equity, Rupee and Gold
31% Rally in 2 Weeks: Orient Electric Stock Jumps Post Q2
Tech Mahindra Dividend, Bonus Share 2026: Should You Buy Ahead of Record Date?
Ambani Taps Massive Reliance Workforce to Boost Jio's Record IPO
RM Drip and Sprinklers System Ltd. Hits Upper Circuit on NSE, 16 October 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





